Open | $26.950 |
Close | $26.840 |
Volume / Avg. | 1.387M / 1.465M |
Day Range | 26.060 - 27.430 |
52 Wk Range | 11.250 - 58.380 |
Market Cap | $1.851B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 52 |
Short Interest | 13.18% |
Days to Cover | 6.21 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Akero Therapeutics (NASDAQ: AKRO) through any online brokerage.
Other companies in Akero Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Avidity Biosciences (NASDAQ:RNA), Syndax Pharmaceuticals (NASDAQ:SNDX), PTC Therapeutics (NASDAQ:PTCT) and Protagonist Therapeutics (NASDAQ:PTGX).
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by UBS on Tuesday, March 5, 2024. The analyst firm set a price target for 42.00 expecting AKRO to rise to within 12 months (a possible 56.48% upside). 20 analyst firms have reported ratings in the last year.
The stock price for Akero Therapeutics (NASDAQ: AKRO) is $26.84 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Akero Therapeutics.
Akero Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Akero Therapeutics.
Akero Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.